Advocating for Evidence Based Marijuana Policy
Category Archives: Dosage
Identifying teens at risk for hashish use
New York University. (2015, April 13). Identifying teens at risk for hashish use. ScienceDaily. Retrieved April 14, 2015 from http://www.sciencedaily.com/releases/2015/04/150413091645.htm
Joseph J. Palamar, Lily Lee, Michael Weitzman. Prevalence and correlates of hashish use in a national sample of high school seniors in the United States. The American Journal of Drug and Alcohol Abuse, 2015; 1 DOI: 10.3109/00952990.2015.1011745
Reclassification of cannabis linked to cannabis psychosis
Source: (As reported in ScienceDaily, July 18, 2013) University of York. (2013, July 18). Reclassification of cannabis linked to cannabis psychosis. ScienceDaily. Retrieved June 1, 2014 from http://www.sciencedaily.com/releases/2013/07/130718101156.htm
Researchers have demonstrated that the change in cannabis declassification in 2009 has coincided with a significant increase in hospital admissions for cannabis psychosis – rather than the decrease it was intended to produce.
Ian Hamilton, Charlie Lloyd, Catherine Hewitt, Christine Godfrey. Effect of reclassification of cannabis on hospital admissions for cannabis psychosis: A time series analysis. International Journal of Drug Policy, 2013; DOI: 10.1016/j.drugpo.2013.05.016
WTR-RI Research & Analysis Team Note:
(The following is an excerpt from abstract of the above noted Journal Reference. It is included here to clarify the references to the British controlled drug categories referenced in the preceding two ScienceDaily summaries. The link to the abstract is http://www.ijdp.org/article/S0955-3959(13)00090-X/abstract)
“The UK Misuse of Drugs Act (1971) divided controlled drugs into three groups A, B and C, with descending criminal sanctions attached to each class. Cannabis was originally assigned by the Act to Group B but in 2004, it was transferred to the lowest risk group, Group C. Then in 2009, on the basis of increasing concerns about a link between high strength cannabis and schizophrenia, it was moved back to Group B. The aim of this study is to test the assumption that changes in classification lead to changes in levels of psychosis. In particular, it explores whether the two changes in 2004 and 2009 were associated with changes in the numbers of people admitted for cannabis psychosis.”
Some truth to the ‘potent pot myth’
Source: (As reported in ScienceDaily, March 18, 2014) Wiley. (2014, March 18). Some truth to the ‘potent pot myth’. ScienceDaily. Retrieved June 9, 2014 from www.sciencedaily.com/releases/2014/03/140318093906.htm
People who smoke high-potency cannabis end up getting higher doses of the active ingredient, new research from the Netherlands shows. Although they reduce the amount they puff and inhale to compensate for the higher strength, they still take in more of the active ingredient than smokers of lower potency cannabis.
Peggy van der Pol, Nienke Liebregts, Tibor Brunt, Jan van Amsterdam, Ron de Graaf, Dirk J. Korf, Wim van den Brink, Margriet van Laar. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.Addiction, 2014; DOI: 10.1111/add.12508